全文获取类型
收费全文 | 72481篇 |
免费 | 5461篇 |
国内免费 | 1092篇 |
专业分类
耳鼻咽喉 | 294篇 |
儿科学 | 3414篇 |
妇产科学 | 974篇 |
基础医学 | 6518篇 |
口腔科学 | 1006篇 |
临床医学 | 9668篇 |
内科学 | 13210篇 |
皮肤病学 | 725篇 |
神经病学 | 1012篇 |
特种医学 | 2613篇 |
外国民族医学 | 1篇 |
外科学 | 7668篇 |
综合类 | 11256篇 |
现状与发展 | 7篇 |
预防医学 | 11130篇 |
眼科学 | 292篇 |
药学 | 5967篇 |
63篇 | |
中国医学 | 1555篇 |
肿瘤学 | 1661篇 |
出版年
2024年 | 114篇 |
2023年 | 1123篇 |
2022年 | 1956篇 |
2021年 | 3154篇 |
2020年 | 3143篇 |
2019年 | 2472篇 |
2018年 | 2446篇 |
2017年 | 2399篇 |
2016年 | 2611篇 |
2015年 | 2806篇 |
2014年 | 5076篇 |
2013年 | 5395篇 |
2012年 | 4898篇 |
2011年 | 5036篇 |
2010年 | 3735篇 |
2009年 | 3528篇 |
2008年 | 3427篇 |
2007年 | 3543篇 |
2006年 | 3286篇 |
2005年 | 2859篇 |
2004年 | 2284篇 |
2003年 | 1914篇 |
2002年 | 1393篇 |
2001年 | 1345篇 |
2000年 | 1084篇 |
1999年 | 1019篇 |
1998年 | 818篇 |
1997年 | 755篇 |
1996年 | 606篇 |
1995年 | 640篇 |
1994年 | 581篇 |
1993年 | 467篇 |
1992年 | 423篇 |
1991年 | 383篇 |
1990年 | 305篇 |
1989年 | 302篇 |
1988年 | 248篇 |
1987年 | 210篇 |
1986年 | 156篇 |
1985年 | 212篇 |
1984年 | 152篇 |
1983年 | 86篇 |
1982年 | 140篇 |
1981年 | 104篇 |
1980年 | 76篇 |
1979年 | 80篇 |
1978年 | 55篇 |
1977年 | 56篇 |
1976年 | 51篇 |
1975年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 探讨糖尿病合并结核潜伏感染的研究现状、热点与前沿。方法 收集Web of Science核心合集于2000年1月1日至2021年11月20日发表的糖尿病合并结核潜伏感染的相关文章,运用CiteSpace 5.8.R3软件进行可视化分析。结果 共纳入英文文献148篇,近20年来该领域发文量呈上升趋势。美国发文量最多(46篇, 31.08%),机构间合作情况的可视化分析共得到个340节点、929条连线,网络密度为0.0161,作者间合作关系的知识图谱共得到790个节点、2425条连线,网络密度为0.0078,关键词共现分析结果显示,糖尿病合并结核潜伏感染的危险因素、患病率、诊断和治疗是该领域的研究热点和趋势。结论 糖尿病合并结核潜伏感染的发文量不断增加,机构间、区域内和国际范围内的合作有待进一步开展。立足国情,探索慢病共病的管理模式将有助于优化共病管理,进一步推动慢病管理的进程。 相似文献
2.
3.
4.
5.
《Archivos de bronconeumología》2022,58(3):246-254
We have updated recommendations on 12 controversial topics that were published in the 2013 National Consensus on the diagnosis, risk stratification and treatment of patients with pulmonary embolism (PE). A comprehensive review of the literature was performed for each topic, and each recommendation was evaluated in two teleconferences. For diagnosis, we recommend against using the Pulmonary Embolism Rule Out Criteria (PERC) rule as the only test to rule out PE, and we recommend using a D-dimer cutoff adjusted to age to rule out PE. We suggest using computed tomography pulmonary angiogram as the imaging test of choice for the majority of patients with suspected PE. We recommend using direct oral anticoagulants (over vitamin K antagonists) for the vast majority of patients with acute PE, and we suggest using anticoagulation for patients with isolated subsegmental PE. We recommend against inserting an inferior cava filter for the majority of patients with PE, and we recommend using full-dose systemic thrombolytic therapy for PE patients requiring reperfusion. The decision to stop anticoagulants at 3 months or to treat indefinitely mainly depends on the presence (or absence) and type of risk factor for venous thromboembolism, and we recommend against thrombophilia testing to decide duration of anticoagulation. Finally, we suggest against extensive screening for occult cancer in patients with PE. 相似文献
6.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献
7.
8.
9.
We present the case of a male patient with severe SARS-CoV-2 pneumonia, with simultaneous onset of p-ANCA positive rapidly progressive glomerulonephritis. We discuss the different therapeutic possibilities, emphasising the appropriateness of their administration according to the time in the course of the infection. 相似文献
10.